Tarsons Products
Tarsons Products Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Tarsons expects growth driven by new product launches including bioprocess and cell culture products over the next 3 to 5 years. Growth expected through new product launches and market share gains both domestically and internationally, particularly in exports.
From Tarsons Products's Q2 FY26 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- Tarsons expects growth driven by new product launches including bioprocess and cell culture products over the next 3 to 5 years.
- Capacity expansion underway (Panchla and Amta facilities) targeting peak revenue potential of INR350-400 crores, with INR100-125 crores from existing products and the rest from new products.
- Ramp-up timeline for full utilization is estimated at 3 to 5 years, with gradual market penetration and customer validation.
- Export market inquiries are strong, with efforts to increase wallet share in both domestic and international markets.
- Domestic market growth is challenged by high competition and price sensitivity; however, new products and increasing brand recall are expected to support incremental revenue.
2 more points from Tarsons Products's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Tarsons Products said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total capex planned between INR550 crores to INR650 crores, covering Panchla, Amta, and existing plants.
- Panchla facility focused on capacity expansion for existing products and launching new products like cell culture products.
- Amta facility includes radiation and sterilization plant, with some manufacturing of existing products starting soon.
- Capex timeline extended due to inflation and foreign exchange fluctuations; expected to be fully commissioned by Q4 FY26.
- Peak asset turnover estimated at 0.7 to 0.8 on gross block level.
- Ramp-up for new products expected over 3 to 5 years; existing product expansion over 2 to 3 years.
2 more points from Tarsons Products's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Tarsons Products said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Tarsons is experiencing a healthy and growing order book across global markets, including the U.S. and other international regions.
- Some orders are delayed or pending due to capacity constraints and ongoing machine commissioning.
- Management is optimistic about export growth by the end of the year, expecting to overcome current shipment delays caused by factors like non-issuance of Bills of Lading.
- Existing customers continue to place orders, with no loss of clients despite tariff challenges.
2 more points from Tarsons Products's call on order book
Pro opens every point from 15K+ earnings calls
Tarsons Products — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹121 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Tarsons Products Ltd's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- QMS Medical Allied Services Ltd (Q2 FY26)
The only related transaction noted is the recent acquisition of Saarathi increasing stake from 51% to 76%, but no fundraising details were shared with respect…
- Vasa Denticity Ltd (Q2 FY26)
Growth levers include increasing active customers (e.g., from 60,000 to 100,000 monthly) and increasing wallet share per customer (e.g., from 15% to 40%). Key…
- Fischer Medical Ventures Ltd (Q2 FY26)
Export markets are growing, contributing about 30% of revenues currently, up from about 5-10% a year ago, indicating international expansion potential. Key…
Arthneeti Pro · Annual
Tarsons Products and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Tarsons Products Q2 FY26 results?
Tarsons expects growth driven by new product launches including bioprocess and cell culture products over the next 3 to 5 years. Growth expected through new product launches and market share gains both domestically and internationally, particularly in exports.
What is Tarsons Products share price analysis?
Tarsons Products currently shows a neutral. The stock trades at a P/E of 155.0 with a market cap of ₹1,835 Cr. Investors should review the full earnings analysis for detailed insights.
Is Tarsons Products planning capital expenditure?
Total capex planned between INR550 crores to INR650 crores, covering Panchla, Amta, and existing plants.
Keep Tarsons Products on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.